{'fraction_non_alphanumeric': 0.0199501246882793, 'fraction_numerical': 0.0, 'mean_word_length': 5.922413793103448, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Diabetes and Coronary Intervention: Special Considerations for Antithrombotic Therapy.

Diabetes mellitus is an increasing problem in the Western world and is associated with a more advanced state of coronary artery disease than that observed in non-diabetic patients. Diabetes mellitus is a prothrombotic state and poses some unique challenges to the interventional cardiologist. The development of more potent antithrombotic therapies has improved the safety and effectiveness of percutaneous coronary intervention (PCI), particularly in high-risk groups such as diabetic patients. This article summarizes the available data on the use of heparins (unfractionated and low molecular weight), intravenous glycoprotein IIb/IIIa blockers, and oral antiplatelet agents in diabetic patients undergoing PCI.